Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.
about
Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systemsHigh-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in TanzaniaEffect of transmission reduction by insecticide-treated bednets (ITNs) on antimalarial drug resistance in western KenyaFitness trade-offs in the evolution of dihydrofolate reductase and drug resistance in Plasmodium falciparumPatterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data.Drug resistance maps to guide intermittent preventive treatment of malaria in African infants.Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin.The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP+artesunate combination.Prevalence of malaria among patients attending public health facilities in Maputo City, Mozambique.Media, health workers, and policy makers' relationship and their impact on antimalarial policy adoption: a population genetics perspective.Molecular markers in plasmodium falciparum linked to resistance to anti-malarial drugs in samples imported from Africa over an eight-year period (2002-2010): impact of the introduction of artemisinin combination therapy.Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized TrialRoutine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study.Alterations in Plasmodium falciparum genetic structure two years after increased malaria control efforts in western Kenya.Genetic diversity and signatures of selection of drug resistance in Plasmodium populations from both human and mosquito hosts in continental Equatorial GuineaTrends in antimalarial drug use in Africa.Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal.Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study.How can we identify parasite genes that underlie antimalarial drug resistance?malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication.High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine.
P2860
Q27000750-F29AD92A-A132-4DBA-85E8-8B8BB606B542Q28125930-066EDDE6-AF6D-4881-999B-B3AD5428CD66Q28477925-CB188D49-9D8A-4F2A-9E03-A950A56DB9DFQ28478215-13AD48B9-57F5-40CD-8B53-C040C013CC44Q33893267-3BE6F6C8-6D72-46E9-B065-7D0204C56A56Q35228689-B5C82D3D-4F15-4B83-A3D6-B92D5DB0E381Q35428566-18000EF2-ED5D-46EE-B8EE-4E6A1FDBB20EQ35541212-958512CE-A56C-4873-8007-7DDC020F35DAQ35576008-5B9E5705-477B-4C6C-971E-44FF2323CF41Q35755266-8AD6BD92-54C0-4B0A-A5EF-CA4932076EADQ36051104-0F5ED3CC-EBA8-43E3-A2B7-75A1C46BAC3BQ36057593-6175E612-4ECB-4E57-897E-2BEB2DB2914BQ36483241-0EB2FD79-8862-4B30-9499-F70D6326817FQ36523046-8077A38B-B20E-4A21-AB03-9A245D537C08Q36752392-2BA919F0-2A05-42E7-9505-09CC8C51863BQ37287647-D69ED8D4-33BE-46CF-93D5-1318272D2612Q37390524-2913EFD4-99BC-4B8D-A978-36205B9F6663Q37558174-D276A3F3-B258-4BD1-80F5-18ED26B42931Q37822758-820F700D-E5C4-4EDE-98C0-A77A25235027Q47132201-2759286C-B188-4CDD-9E5D-CC503D36E158Q47566100-7C5A7937-2485-4225-B40D-1F0590C16AC4
P2860
Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@ast
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@en
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@nl
type
label
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@ast
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@en
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@nl
prefLabel
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@ast
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@en
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Drug coverage in treatment of ...... of sulphadoxine/pyrimethamine.
@en
P2093
Allen L Malisa
Patrick S Kachur
Peter Bloland
Richard J Pearce
P2860
P2888
P356
10.1186/1475-2875-9-190
P577
2010-07-05T00:00:00Z
P5875
P6179
1006514730